Juan Frias
Chief Tech/Sci/R&D Officer at BIOMEA FUSION, INC.
Net worth: 3 671 $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ramses Erdtmann | M | 60 | 7 years | |
Tom Butler | M | 43 | 7 years | |
William Hait | M | 74 | 17 years | |
Michael Hitchcock | M | 74 | 3 years | |
Naomi Cretcher | F | - | 17 years | |
Franco Valle | M | 43 | 3 years | |
Steve Morris | M | - | 4 years | |
David Walton | M | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | 6 years |
Peter Fasolo | M | 61 | 18 years | |
Elizabeth Faust | M | 59 | 2 years | |
Eric Aguiar | M | 62 | 4 years | |
Bihua Chen | F | 55 | 4 years | |
Anne Mulcahy | F | 70 | 15 years | |
Sumita Ray | F | 50 | 3 years | |
Alex Cacovean | M | - | 3 years | |
Nicole Rioles | F | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | - |
Priyanka Mandava | F | - | - | |
Hanna Cho | M | - | - | |
Terrie Phan | F | - | 3 years | |
Anthony Souza | M | - | 9 years | |
Richard Altinger | M | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | 4 years |
Thorsten Kirschberg | M | 54 | 4 years | |
Rebecca Parkes | F | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | - |
Henry Anhalt | M | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | 9 years |
Jack Collins | M | - |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | 6 years |
Heow Tan | M | 65 | 4 years | |
Abbie Celniker | M | 65 |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | - |
John Brooks | M | 73 |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | 4 years |
Chun Yi Zhao | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Juan Frias
- Personal Network